Long-term results of Nivolumab + Cabozantinib in RCC

Published Date: 08 Mar 2023

The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

In Patients with Myeloma Who Postpone HSCT, Quadruplet Displays "Excellent Activity.".

2.

Can patients receiving immunotherapy for cancer benefit from taking vitamin D supplements?

3.

FDA approves Blenrep for relapsed or refractory multiple myeloma

4.

Novel topical fluorescent imaging technique rapidly and safely detects basal cell carcinoma

5.

New CAR-T Drug Induces Durable Remissions in ALL, Published Data Show


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot